Yochanra®, the World's First Innovative Drug to Overcome FGFR Inhibitor Resistance, Makes Its Global Debut in China - Thailand PR News - [Banking](https://thailandbusinessnews.net/category/banking/) - [Companies](https://thailandbusinessnews.net/category/companies/) - [Economy](https://thailandbusinessnews.net/category/economy/) - [Press Releases](https://thailandbusinessnews.net/category/press-release/) - [PR Newswire](https://thailandbusinessnews.net/pr-newswire-updates/) - [Tech](https://thailandbusinessnews.net/category/tech/) - [Tourism](https://thailandbusinessnews.net/category/tourism/) - [Press Release](https://thailandbusinessnews.net/category/press-release/) # Yochanra®, the World's First Innovative Drug to Overcome FGFR Inhibitor Resistance, Makes Its Global Debut in China ##### Up next ![FAMILIARITÉ: A Poetic Convergence of Cinema and Literature](https://i0.wp.com/mmx.prnasia.com/media/MS1965358/20260806085633EDT_image_1.jpg?resize=200%2C110&ssl=1 "FAMILIARITÉ: A Poetic Convergence of Cinema and Literature") [](https://thailandbusinessnews.net/press-release/familiarite-a-poetic-convergence-of-cinema-and-literature/) ###### [FAMILIARITÉ: A Poetic Convergence of Cinema and Literature](https://thailandbusinessnews.net/press-release/familiarite-a-poetic-convergence-of-cinema-and-literature/) Published on 07 August 2026 ##### Author ##### [ CISION PRNewswire ](https://thailandbusinessnews.net/author/cision/) ##### Tags - [PRNewswire](https://thailandbusinessnews.net/tag/prnewswire/) NANJING, China and GAITHERSBURG, Md., Aug. 7, 2026 /PRNewswire/ — TransThera Sciences’ Yochanra® is the first drug independently developed in China to address the longstanding global challenge of acquired resistance to FGFR inhibitor therapy in patients with cholangiocarcinoma. On 6 August 2026, the National Medical Products Administration (the "NMPA") formally approved the drug for marketing. As a global frontrunner in this field, the product had previously been granted Fast Track Designation and Orphan Drug Designation by the U.S. Food and Drug Administration (the "FDA"), Orphan Drug Designation for the treatment of biliary tract cancer by the European Medicines Agency (the "EMA"), and inclusion in the List of Products for Priority Review and the List of Breakthrough Therapeutic Drugs by the NMPA in China. The product has also been featured and presented orally on multiple occasions at leading international scientific conferences, filling the clinical gap arising from the absence of a standard treatment following the development of resistance to FGFR inhibitor therapy. The indication approved by the NMPA is the first indication under the multi-indication development strategy for Yochanra®. It is indicated for adult patients with advanced, metastatic or unresectable cholangiocarcinoma harboring an FGFR2 fusion or rearrangement who have previously received systemic therapy and FGFR inhibitor therapy. The approval of this indication was based on a multicenter, open-label, single-arm, pivotal Phase II clinical trial conducted in China. The results of the study were presented at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO). As of 27 December 2025, with a median follow-up of 12 months, all 50 patients with advanced cholangiocarcinoma enrolled in the study had previously received at least one line of chemotherapy and treatment with one FGFR inhibitor. Assessments by blinded independent central review (BICR) showed that: - The objective response rate (ORR) was 28.0%, with 14 patients achieving a confirmed partial response. The median duration of response (DoR) was 8.5 months (95% CI: 5.6~12.5 months), and the disease control rate (DCR) was 82.0%. - The median progression-free survival (PFS) was 6.0 months (95% CI: 4.4~8.3 months). - The median overall survival (OS) was 20.7 months (95% CI: 11.8 months ~ not estimable). In the trial, Yochanra® demonstrated durable antitumor activity and a manageable safety and tolerability profile. The global market for cholangiocarcinoma therapeutics reached US$2.0 billion in 2024 and is projected to grow to US$3.2 billion by 2027, with approximately 25.2% of patients with cholangiocarcinoma harboring FGFR alterations. According to a research paper published in "Cancer Treatment Reviews" in 2023, patients with cholangiocarcinoma develop acquired resistance following FGFR inhibitor treatment. Patients who develop resistance typically harbor at least one, and often multiple, mutations, creating extremely high barriers to drug development in this field. Several overseas biotech companies have initiated related research programs, but such programs ultimately ended in failure. Neither Chinese nor U.S. treatment guidelines provide any high-level recommendation for the treatment of patients with cholangiocarcinoma who have developed resistance, leaving such patients without an established standard treatment option. Through its unique FGFR-binding mode, Yochanra® can overcome resistance mutations at multiple sites while maintaining high binding activity. Clinical trials have demonstrated that it can effectively overcome acquired resistance, bringing new hope to patients with FGFR2 fusion- or rearrangement-positive cholangiocarcinoma who have developed resistance to prior FGFR inhibitor therapy. This marketing approval marks the approval in China of the first indication for Yochanra®. Meanwhile, for cholangiocarcinoma, enrollment has been completed in the global multicenter registrational Phase III study of Yochanra®, while the Phase III confirmatory study in China is progressing in parallel. For other indications, the Company will continue to advance clinical trials at various stages, with a view to providing potentially better clinical treatment options for more patients, including, but not limited to, patients with prostate cancer, breast cancer and liver cancer. **ABOUT YOCHANRA®** Yochanra® (Tinengotinib) is an innovative multi-target small-molecule kinase inhibitor independently developed by the Company targeting FGFR/VEGFR, JAK and Aurora kinases. It exerts antitumor effects through three mechanisms: precision targeting, lineage remodeling and immune activation. Yochanra® is currently being evaluated in multiple clinical trials conducted globally for solid tumors including cholangiocarcinoma, prostate cancer, breast cancer and liver cancer. It has been granted Orphan Drug Designation and Fast Track Designation by the U.S. FDA for the treatment of cholangiocarcinoma and Orphan Drug Designation by the EMA for the treatment of biliary tract cancer. **ABOUT TRANSTHERA** TransThera is a biopharmaceutical company that focuses on clinical needs. It is dedicated to discovering and developing small molecule innovative therapies for tumors, inflammation, and cardiometabolic diseases. Further aided by in-depth study of translational medicine and drug design, TransThera aims to develop first-in-class or best-in-class drug candidates strategically positioned to meet urgent clinical needs on a global scale. [Source link ](http://www.prnasia.com/story/archive/5021651_CN21651_0?rand=89749) ``` This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network ``` ##### You May Also Like [](https://thailandbusinessnews.net/press-release/desilos-encrypted-llm-breakthrough-recognized-by-acm-ccs-2025-paving-the-way-for-privacy-safe-ai-products/) ![DESILO's Encrypted LLM Breakthrough Recognized by ACM CCS 2025, Paving the Way for Privacy-Safe AI Products](https://i0.wp.com/r2.thailandbusinessnews.net/2025/09/1758807621_1.jpg?resize=260%2C140&ssl=1 "DESILO's Encrypted LLM Breakthrough Recognized by ACM CCS 2025, Paving the Way for Privacy-Safe AI Products") - [Press Release](https://thailandbusinessnews.net/category/press-release/) ## DESILO's Encrypted LLM Breakthrough Recognized by ACM CCS 2025, Paving the Way for Privacy-Safe AI Products SEOUL, South Korea, Sept. 25, 2025 /PRNewswire/ — DESILO Inc. today announced… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - September 25, 2025 [](https://thailandbusinessnews.net/press-release/nyse-content-advisory-pre-market-update-small-business-optimism-improves/) ## NYSE Content Advisory: Pre-Market update + Small business optimism improves NEW YORK, June 10, 2025 /PRNewswire/ — The New York Stock Exchange… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - June 10, 2025 [](https://thailandbusinessnews.net/press-release/dubai-fountain-undergoes-a-stunning-revamp-temporary-closure-announced-for-upgrade-and-enhancement/) ![Dubai Fountain Undergoes a Stunning Revamp: Temporary Closure Announced for Upgrade and Enhancement](https://i0.wp.com/r2.thailandbusinessnews.net/2025/02/Emaar_Dubai_Fountain.jpg?resize=260%2C140&ssl=1 "Dubai Fountain Undergoes a Stunning Revamp: Temporary Closure Announced for Upgrade and Enhancement") - [Press Release](https://thailandbusinessnews.net/category/press-release/) ## Dubai Fountain Undergoes a Stunning Revamp: Temporary Closure Announced for Upgrade and Enhancement Starting in May, the iconic attraction will be closed for five months… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - February 5, 2025 ##### Most Read - [![Finloop Raises Over US$10 Million in Series A+ Financing, Welcomes HSBC as One of its Strategic Investors, and Launches Its Corporate Service "Finterprise"](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/finloop-raises-over-us10-million-in-series-a-financing-welcomes-hsbc-as-one-of-its-strategic-investors-and-launches-its-corporate-service-finterprise/ "Finloop Raises Over US$10 Million in Series A+ Financing, Welcomes HSBC as One of its Strategic Investors, and Launches Its Corporate Service "Finterprise"") [Finloop Raises Over US$10 Million in Series A+ Financing, Welcomes HSBC as One of its Strategic Investors, and Launches Its Corporate Service "Finterprise"](https://thailandbusinessnews.net/press-release/finloop-raises-over-us10-million-in-series-a-financing-welcomes-hsbc-as-one-of-its-strategic-investors-and-launches-its-corporate-service-finterprise/ "Finloop Raises Over US$10 Million in Series A+ Financing, Welcomes HSBC as One of its Strategic Investors, and Launches Its Corporate Service "Finterprise"") - [![Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/chubb-wealth-debuts-evergreen-private-markets-fund-series-with-s64/ "Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64") [Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64](https://thailandbusinessnews.net/press-release/chubb-wealth-debuts-evergreen-private-markets-fund-series-with-s64/ "Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64") - [![Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/triton-uranium-advances-atlas-project-reports-exploration-target-of-46-56-million-pounds-of-uranium/ "Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium") [Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium](https://thailandbusinessnews.net/press-release/triton-uranium-advances-atlas-project-reports-exploration-target-of-46-56-million-pounds-of-uranium/ "Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium") - [![Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/adecco-group-announces-salesforces-agentforce-coworker-rollout-across-40-countries/ "Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries") [Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries](https://thailandbusinessnews.net/press-release/adecco-group-announces-salesforces-agentforce-coworker-rollout-across-40-countries/ "Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries") - [![GCCL and Medicover Integrated Clinical Services Announce Strategic Collaboration to Strengthen Multinational Clinical Trial Services](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/gccl-and-medicover-integrated-clinical-services-announce-strategic-collaboration-to-strengthen-multinational-clinical-trial-services/ "GCCL and Medicover Integrated Clinical Services Announce Strategic Collaboration to Strengthen Multinational Clinical Trial Services") [GCCL and Medicover Integrated Clinical Services Announce Strategic Collaboration to Strengthen Multinational Clinical Trial Services](https://thailandbusinessnews.net/press-release/gccl-and-medicover-integrated-clinical-services-announce-strategic-collaboration-to-strengthen-multinational-clinical-trial-services/ "GCCL and Medicover Integrated Clinical Services Announce Strategic Collaboration to Strengthen Multinational Clinical Trial Services") - [![600 Clubs Strong: Inspire Brands Asia Continues Regional Expansion, Affirms Vision for 1,000 by 2028](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/600-clubs-strong-inspire-brands-asia-continues-regional-expansion-affirms-vision-for-1000-by-2028/ "600 Clubs Strong: Inspire Brands Asia Continues Regional Expansion, Affirms Vision for 1,000 by 2028") [600 Clubs Strong: Inspire Brands Asia Continues Regional Expansion, Affirms Vision for 1,000 by 2028](https://thailandbusinessnews.net/press-release/600-clubs-strong-inspire-brands-asia-continues-regional-expansion-affirms-vision-for-1000-by-2028/ "600 Clubs Strong: Inspire Brands Asia Continues Regional Expansion, Affirms Vision for 1,000 by 2028") ##### Subscribe via Email Enter your email address to subscribe and receive notifications of new posts by email. Email Address Subscribe [](https://thailandbusinessnews.net/press-release/banyan-group-announces-acquisition-of-newmark-hotels-reserves-adding-26-hotels-lodges-and-reserves-across-seven-african-countries/) ![Banyan Group Announces Acquisition of Newmark Hotels & Reserves, Adding 26 Hotels, Lodges, and Reserves Across Seven African Countries](https://i0.wp.com/mmx.prnasia.com/media/MS1990742/20260917065723EDT_image_1.jpg?resize=260%2C140&ssl=1 "Banyan Group Announces Acquisition of Newmark Hotels & Reserves, Adding 26 Hotels, Lodges, and Reserves Across Seven African Countries") ## Banyan Group Announces Acquisition of Newmark Hotels & Reserves, Adding 26 Hotels, Lodges, and Reserves Across Seven African Countries Newmark’s deep regional expertise across urban, nature and wildlife hospitality… [](https://thailandbusinessnews.net/press-release/xpeng-launches-its-next-gen-ai-flagship-suv-g9l-in-china-with-global-launch-set-for-oct-12-at-the-paris-motor-show/) ![XPENG Launches Its Next-Gen AI Flagship SUV G9L in China, with Global Launch Set for Oct 12 at the Paris Motor Show](https://i0.wp.com/mmx.prnasia.com/media/MS1990789/20260917090347EDT_image_1.jpg?resize=260%2C140&ssl=1 "XPENG Launches Its Next-Gen AI Flagship SUV G9L in China, with Global Launch Set for Oct 12 at the Paris Motor Show") ## XPENG Launches Its Next-Gen AI Flagship SUV G9L in China, with Global Launch Set for Oct 12 at the Paris Motor Show XPENG announces that the G9L will be launched in 64 global markets,… [](https://thailandbusinessnews.net/press-release/cellebrite-expands-global-digital-community-the-101-for-digital-forensics-and-investigative-professionals/) ![Cellebrite Expands Global Digital Community, 'The 101', for Digital Forensics and Investigative Professionals](https://i0.wp.com/mmx.prnasia.com/media/MS1775952/Cellebrite-Logo.jpg?resize=260%2C140&ssl=1 "Cellebrite Expands Global Digital Community, 'The 101', for Digital Forensics and Investigative Professionals") ## Cellebrite Expands Global Digital Community, 'The 101', for Digital Forensics and Investigative Professionals Purpose-built platform connects customers worldwide with peers and Cellebrite experts… [](https://thailandbusinessnews.net/press-release/eightco-holdings-nasdaq-orbs-reports-total-holdings-of-approximately-380-million-includes-openai-beast-industries-more-than-16000-eth-and-nearly-302-million-wld-tokens-2/) ![Eightco Holdings (NASDAQ: ORBS) Reports Total Holdings of Approximately 0 Million, Includes OpenAI, Beast Industries, More Than 16,000 ETH and Nearly 302 Million WLD Tokens](https://i0.wp.com/mmx.prnasia.com/media/MS695659/Eightco-Logo.jpg?resize=260%2C140&ssl=1 "Eightco Holdings (NASDAQ: ORBS) Reports Total Holdings of Approximately 0 Million, Includes OpenAI, Beast Industries, More Than 16,000 ETH and Nearly 302 Million WLD Tokens") ## Eightco Holdings (NASDAQ: ORBS) Reports Total Holdings of Approximately $380 Million, Includes OpenAI, Beast Industries, More Than 16,000 ETH and Nearly 302 Million WLD Tokens Eightco treasury composition as of September 16, 2026: $90M OpenAI equity (indirect),…